新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 乙肝 » Clin Gastr & Hepatol:抗病毒疗法或可抑制乙肝患者肝细胞癌的发生

Clin Gastr & Hepatol:抗病毒疗法或可抑制乙肝患者肝细胞癌的发生

来源:生物谷 2014-06-11 10:48

2014年6月11日 讯 /生物谷BIOON/ --近日,刊登在国际杂志Clinical Gastroenterology and Hepatology上的一篇研究论文中,来自亚特兰大疾病预防控制中心的研究人员通过研究发现,抗病毒疗法或许可以成功抑制乙型肝炎病人发展为肝细胞癌(肝癌的一种形式)。

文章中,研究者对超过2600名运用抗病毒疗法治疗的乙肝病毒患者进行分析研究,进行长达5年的抗病毒疗法后患者患肝细胞癌的发生率明显降低了;总的来讲在研究期间有3%的患者发生了肝细胞癌,相比未接受抗病毒疗法的患者来讲,接受抗病毒疗法的病人中60%的个体患肝细胞癌的可能性都较小。

Stuart C. Gordon博士表示,研究结果显示,抗病毒疗法实际上降低乙肝患者患肝癌的风险,在美国肝细胞癌在肝癌患者中占据了较大的比例,在50岁及以上的男性个体中肝细胞癌尤为常见;如果癌症不能得到及时治疗,其通常在3-6个月里是非常危险的。在很多病例中肝细胞癌是由于肝脏结疤(肝硬化)而致,而饮酒、乙肝以及肝脏的慢性炎症是引发肝硬化的主要原因。

最后,研究者Joseph Boscarino表示,这项研究首次揭示了抗病毒疗法和抑制乙肝患者患肝癌之间的关联,基于本文的数据,临床医生们就可以根据患者自身的状况来进行一定的抗病毒疗法来抑制乙肝患者肝癌的发生。(生物谷Bioon.com)

Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population

Stuart C. Gordon, Lois E. Lamerato, Loralee B. Rupp, Jia Li, Scott D. Holmberg, Anne C. Moorman, Philip R. Spradling, Eyasu H. Teshale, Vinutha Vijayadeva, Joseph A. Boscarino, Emily M. Henkle, Nancy Oja–Tebbe, Mei Lu.

Background & Aims Antiviral therapy could reduce the risk of hepatocellular carcinoma (HCC) among persons with chronic hepatitis B virus (HBV) infection. We evaluated the relationship between therapy for chronic HBV infection and HCC incidence using data from a longitudinal study of patients at 4 US healthcare centers. Methods We analyzed electronic health records of 2671 adult participants in the Chronic Hepatitis Cohort Study who were diagnosed with chronic HBV infection from 1992 through 2011 (49% Asian). Data analyzed were collected for a median of 5.2 years. Propensity-score adjustment was used to reduce bias, and Cox regression was used to estimate the relationship between antiviral treatment and HCC. The primary outcome was time to event of HCC incidence. Results Of study subjects, 3% developed HCC during follow-up period: 20 cases among the 820 patients with a history of antiviral HBV therapy and 47 cases among the 1851 untreated patients. In propensity-adjusted Cox regression, patients who received antiviral therapy had a lower risk of HCC than those who did not receive antiviral therapy (adjusted hazard ratio, 0.39; 95% confidence interval, 0.27–0.56; P < .001), after adjusting for abnormal level of alanine aminotransferase. In a subgroup analysis, antiviral treatment was associated with a lower risk of HCC after adjusting for serum markers of cirrhosis (adjusted hazard ratio, 0.24; 95% confidence interval, 0.15–0.39; P < .001). In a separate subgroup analysis of patients with available data on HBV DNA viral load, treated patients with viral loads >20,000 IU/mL had a significantly lower risk of HCC than untreated patients with viral loads >20,000 IU/mL. Conclusions In a large geographically, clinically, and racially diverse US cohort, antiviral therapy for chronic HBV infection was associated with a reduced risk for HCC.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库